Abstract
Lyngbyastatin 7 is marine-derived cyanobacterial cyclodepsipeptide that showed better potency towards inhibiting elastase than sivelestat, the only approved drug targeting this enzyme. The discovery of elastase inhibitors is of great importance since this enzyme plays a significant role in several pulmonary diseases, such as chronic obstructive pulmonary disease, the third leading cause of death worldwide. We established the first total synthesis of lyngbyastatin 7 and validated the elastase-inhibitory activity in enzyme assays. Lyngbyastatin 7 also outperformed sivelestat in our cellular assays, where the compound protected human bronchial epithelial cells against elastase-induced antiproliferative effects as well as attenuated the transcription of sICAM-1 and IL1β which are induced by elastase. The synthetic accessibility overcomes the supply issue and paves the way for the synthesis of diverse analogues with the goal of discovering effective therapeutics against elastase-mediated pathologies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
